MassDevice Q&A

June 30, 2009 by MassDevice staff

Q&A Features

12/02/2014 by MassDevice

The FDA grants de novo clearance to HeartFlow's novel system for non-invasive measurement of fractional flow reserve, which CEO Dr. John Stevens calls "the gold standard" for diagnosing and treating coronary disease.

HeartFlow wins FDA OK for non-invasive FFR system

By Brad Perriello and Mark Hollmer

HeartFlow yesterday said it won de novo clearance from the FDA...

12/02/2014 by Brian Johnson

Caroll Neubauer, the CEO of B. Braun Medical, sits down for a wide-ranging interview on the hottest topics facing the medical device industry.


Caroll Neubauer is a man of strong opinions.

Fortunately for us, the chairman & CEO of 175-year-old German medical products conglomerate B. Braun Medical isn't afraid to share those opinions – even though he admits that they occaisionally get him into trouble. A case in point, as you'll hear in this podcast, is Neubauer's passionate...

10/27/2014 by Brad Perriello

Sequent Medical CEO Tom Wilder tells why his company's MicroBraid technology is a key differentiator in its Web device for treating brain aneurysms and, potentially, other conditions.

Sequent Medical CEO Wilder bets on braids

Sequent Medical CEO Tom Wilder estimates that the global market for neuro-interventional devices is worth about $1.2 billion. But there's an aspect...

10/24/2014 by Brian Johnson

In this DeviceTalks preview, we catch up with Masimo CEO Joe Kiani to discuss new challenges facing the company and how medtech can break the cycle of the era of 'good-enough' innovation.

Masimo's Kiani on 'good-enough innovation,' Medtronic, Apple and 25 years of pushing the envelope

Twenty-five years have done little to diminish the fire inside Joe Kiani and Irvine, Calif. -based...

10/01/2014 by Brian Johnson

Orange County, Calif.'s most-connected man, OCTANe's Matthew Jenusaitis talks to about OCTANe's 2014 Medical Device Investor Forum.

OCTANe's Matthew Jenusaitis

OCTANe, the industry council responsible for promoting the innovation climate in Orange County, Calif., existed before Matthew Jenusaitis arrived, but he has put his mark on the organization's impact on one of the world's largest med tech clusters.

Jenusaitis' medtech pedigree, which includes 15 years at Boston Scientific (NYSE:...

09/24/2014 by Brad Perriello

Blame the medical device tax and the U.S. regulatory environment for the slump in investment in early-stage medical technologies, Silicon Valley Bank's Ben Johnson tells

What's behind the slump in early-stage medtech investment?

It's a hard world out there for those looking to turn their cutting edge medical device ideas into commercial products, with investors shying away from...

Syndicate content
Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp